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Over the last decade, striking progress has been made in the field of organ
transplantation, such as better surgical expertise and preservation techniques. Therefore,
organ transplantation is nowadays considered a successful treatment in end-stage
diseases of various organs, e.g. the kidney, liver, intestine, heart, and lungs. However,
there are still barriers which prevent a lifelong survival of the donor graft in the recipient.
Activation of the immune system is an important limiting factor in the transplantation
process. As part of this pro-inflammatory environment, the complement system is
triggered. Complement activation plays a key role in the transplantation process, as
highlighted by the amount of studies in ischemia-reperfusion injury (IRI) and rejection.
However, new insight have shown that complement is not only activated in the later
stages of transplantation, but already commences in the donor. In deceased donors,
complement activation is associated with deteriorated quality of deceased donor
organs. Of importance, since most donor organs are derived from either brain-dead
donors or deceased after circulatory death donors. The exact mechanisms and the
role of the complement system in the pathophysiology of the deceased donor have
been underexposed. This review provides an overview of the current knowledge on
complement activation in the (multi-)organ donor. Targeting the complement system
might be a promising therapeutic strategy to improve the quality of various donor organs.
Therefore, we will discuss the complement therapeutics that already have been tested in
the donor. Finally, we question whether complement therapeutics should be translated
to the clinics and if all organs share the same potential complement targets, considering
the physiological differences of each organ.
Keywords: complement system, complement therapeutics, donor management, organ donor, deceased after
brain death, deceased after circulatory death
INTRODUCTION
Donor Condition
Organ transplantation is the gold standard treatment for end-stage diseases in various organs,
including the kidney, liver, intestine, heart, and lungs (1). The field of organ transplantation has
made enormous progress over the last decades. From immunosuppression and tissue matching
to organ procurement and preservation, all these developments significantly contributed to the
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progress made in the field of transplantation (2). Nevertheless,
donor availability and quality are still important limitations.
Organs are mostly retrieved from deceased donors, and to
much lesser extent from living donors (Figure 1). Deceased
donors include donation after brain death (DBD) and donation
after circulatory death (DCD). The DCD donor can be divided
into “expected” and “unexpected”. Expected DCD donation
takes place after planned withdrawal of life-sustaining ventilator
support. In contrast, unexpected death refers to a donor who had
an unanticipated cardiac arrest, without successful resuscitation.
Due to the seizure of circulation, DCD-derived organs have a
variable period of warm ischemia time prior to retrieval (3). Since
the past few years, the number of DCD donors is increasing,
in particular in Belgium, Spain, The United Kingdom and The
Netherlands. However, within Europe, most organs are still
retrieved from DBD donors (Figure 2).
Brain death is the irreversible, total loss of brain function.
Due to artificial ventilation and cardiovascular support, the
circulation remains intact. Therefore, DBD donors do not have
a nominable time of warm ischemia. The occurrence of brain
death is an important risk factor for organ quality since brain
death is associated with a cascade of hemodynamic, hormonal
and immunologic events that become operational after brain
injury, or/and brain death (6). Intracranial events leading to brain
death promote the disruption of the blood-brain barrier integrity
and the neurovascular system, which results in vascular leakage,
edema, and hemorrhage. With these changes an immediate
rise in intracranial pressure occurs, which causes hypoperfusion
of the brain and brainstem. Ischemia of the medulla leads
to sympathetic hyperactivation which causes a catecholamine
storm, and subsequently a rise of the mean arterial pressure
and peripheral vasoconstriction. Activation of the sympathetic
nervous system activates the parasympathetic nervous system as
well, resulting in bradycardia. This physiological nervous system
response is also known as the Cushing response. In addition,
brain ischemia results into damage of the hypothalamus-
pituitary-axis, causing hormonal depletion. As a consequence,
plasma levels of all hormones are lower in DBD donors.
Depletion of the antidiuretic hormone increases diuresis as well
as the risk for hypovolemia in the DBD donor. Last but not
least, the immune system responds quickly to brain injury with
Abbreviations: ALAT, Alanine aminotransferase; AP, Alternative pathway; AR,
Acute rejection; ARDS, Acute respiratory distress syndrome; ASAT, Aspartate
aminotransferase; C1-INH, C1-inhibitor; C3aR, C3a receptor; C5aR1, C5a
receptor 1; C5aR2, C5a receptor 2; CF, Cystic fibrosis; CP, Classical pathway;
COPD, Chronic obstructive pulmonary disease; CRIg, Complement receptor
immunoglobulins; DAMPs, Damage-associated molecular pattern molecules;
DBD, Donation after brain death; DCD, Donation after circulatory death;
DGF, Delayed graft function; ECD, Extended-criteria donor; HTx, Heart
transplantation; IgM, Immunoglobulin; ITx, Intestinal transplantation; IPF,
Idiopathic pulmonary fibrosis; IRI, Ischemia-reperfusion injury; LiTx, Liver
transplantation; LP, Lectin pathway; LPS, Lipopolysaccharides; LuTx, Lung
transplantation; LVAD, Left ventricular assist device; MAC, Membrane attack
complex; MASP, Mannan-binding lectin-associated serine protease; MBL,
Mannose-binding lectin; RTx, Renal transplantation; PAMPs, Pathogen-associated
molecular pattern molecules; PPAH, Primary pulmonary arterial hypertension;
sC5b-9, Soluble C5b-9; SCD, Standard-criteria donor; sCR1, Soluble complement
receptor-1; SNP, Single nucleotide polymorphism; UW, University of Wisconsin.
FIGURE 1 | Overview of donor types. Organs are retrieved from living and
deceased organ donors. Organs from living donors can be donated partially,
so-called “splitted” organ donation, or as a whole organ. The rest of the
organs are retrieved from deceased donors, either from brain death (DBD)
donors or circulatory death (DCD) donors. The DBD donor includes brain
death with an intact circulation and preserved respiration. DCD donation refers
to a donor with a cardiac arrest or loss of cardiac function, occurred before
procurement of the organs. DCD donation can be divided in both expected
and unexpected donation. Expected DCD donation refers to the procurement
of organs after a planned withdrawal of life-sustaining treatments. Unexpected
DCD donation refers to a donor with unexpected cardiac arrest, from which
this donor could not be resuscitated. The quality of organs retrieved from
deceased donors are variable, therefore deceased organs are classified into
two groups: standard-criteria donors or extended-criteria donors (ECD). This
subdivision is introduced to reflect the quality of the organ, of which ECD
include potential donor organs that do not match standard donor criteria.
DBD, donation after brain death; DCD, donation after circulatory death; SCD,
standard criteria donor; ECD, extended criteria donor.
both a sterile and non-sterile immune reaction. Concerning the
DCD donor, only a few experimental studies have investigated
the pathophysiological processes following circulatory arrest in
the target organs. These studies show that apoptosis is one of the
most important pathways of injury in DCD donors, in contrast
to the inflammatory pathways in DBD donors. Whole genome
microarray analyses performed by Damman et al. support these
findings, which observed enriched NOD-like receptor pathways
in DCD reperfusion biopsies. These results suggest that tissue
hypoxia in deceased organs leads to cell necrosis and the release
of damage-associated molecular pattern molecules (DAMPs).
In addition, the study demonstrates that the multiple hypoxia-
related pathways found in DCD reperfusion biopsies are related
with delayed graft function (DGF) (7).
Currently, deceased donors represent the primary source
for transplanted organs. However, the increasing demand for
organ transplants mandates for expansion of the donor pool.
Therefore, alternative strategies are deployed, such as an increase
of the number of living donors, extension of the criteria for
deceased donation and improvements in donormanagement and
procurement (8). Still, continuing efforts to improve and preserve
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FIGURE 2 | The number of donor organs transplanted in 2017, as
documented by Eurotransplant, per type of donor, per organ (4, 5). *In 2017,
the number of intestines donated was six. DBD, donation after brain death;
DCD, donation after cardiac death. The data was consulted on the 25th of
October 2018, permission for publication was obtained.
donor organs are important, for which interventions in the
donor seem a promising strategy. During the last decade, several
donor pretreatment interventions have been explored in both
animal and human studies, like the effect of thyroid hormone
treatment and steroid treatment (9–11). However, no consensus
has been reached regarding these donor treatment strategies,
due to inconsistent results (12). Nevertheless, (pre)treatment of
the deceased donor or the separate donor organs provides us
a window of opportunity to improve graft function and graft
survival. In the search for the optimal target in the donor, the
complement system might play an important role.
THE COMPLEMENT SYSTEM
When the complement system was discovered more than
a century ago, it was described as “heat-labile components
in serum, complementing antibodies in eliminating bacteria.”
Nowadays, the complement system is known as a part of the
innate immune system that consists of over 50 proteins in plasma
and on cell surfaces. In brief, the complement system contains
three activation pathways: the classical pathway (CP), lectin
pathway (LP), and the alternative pathway (AP). The CP was
the first pathway discovered and is activated by antigen-antibody
complexes. These complexes are recognized by C1q, inducing
a cascade via C2 and C4, leading to the production of CP C3
convertase (C4b2b). The same result is achieved when pattern
recognition molecules of the LP [mannose-binding lectin (MBL),
ficolins or collectin-11] bind to their MBL-associated serine
proteases (MASP) to cleave C2 and C4. The AP is spontaneously
activated by hydrolysis of C3 to C3(H2O). Factor B is recruited
and cleaved by factor D to form the AP C3 convertase (C3bBb).
These convertases are intrinsically unstable, but their half-life is
lengthened by interaction with factor properdin (P), a positive
stabilizing regulator of the AP (13). The C3 convertases formed
by the different pathways are responsible for a low grade cleavage
of C3, thereby forming C3b. C3b mediates opsonization or
binds to the C3 convertase to form the C5 convertase. The
C5-convertases cleave C5 into C5a and C5b after which the
membrane attack complex (MAC) is formed, via attachment
of C5b to C6, C7, C8, and C9. The MAC complex induces
the formation of lipophilic complexes in cell membranes which
finally leads to cell lysis. Furthermore, C5b-9 induces tissue
injury via intra-cellular pro-inflammatory signaling pathways
(14). Finally, injury can be amplified by the formed split products
C3a and C5a, acting as anaphylatoxins that provoke influx and
activation of inflammatory cells (15, 16).
The Complement System in the Organ
Donor
Under normal circumstances, the complement system is strictly
controlled by complement regulators to prevent the destruction
of healthy cells and tissues (15). However, when this fine balance
is disturbed, the activated complement system may result in
tissue injury. Damman et al. demonstrated the involvement
of complement activation in deceased organ donors (17). In
both DBD and DCD donors, increased systemic complement
levels of C5b-9 were found in plasma, compared to C5b-9
levels of living donors. These higher complement levels were
associated with increased local tissue injury in deceased donors
compared to the living counterparts. Deceased donors also have
a higher incidence of acute rejection in renal allografts (17).
Van Werkhoven et al. showed an additional upregulation of
C5a in plasma from DBD donors compared to living controls
(18). Furthermore, De Vries et al. demonstrated that soluble
C5b-9 (sC5b-9) release is detected in both DBD and DCD
donors before reperfusion, but not in living donors (19). These
higher levels of sC5b-9 in deceased donors are associated with
inferior renal allograft function after transplantation (20). In
accordance, systemic C4d and Bb levels were significantly higher
in the deceased donor than in the living counterpart, with both
complement proteins being associated with sC5b-9 levels in the
DBD donor. Interestingly, there was no association seen between
MBL and sC5b-9, which suggests that both the CP and AP are
involved in brain death injury, but not the LP. However, with
the recent findings of the potential bypasses in the complement
system, the LP might still play a role in complement activation
in the deceased donor (21, 22). Not only in kidneys, but also
in lungs it has been demonstrated that plasma complement
levels correlate with tissue injury after transplantation. Shah
et al. measured plasma complement levels in recipients before
transplantation and found an association with risk for acute lung
injury and a higher incidence of mortality in lung transplant
recipients (23). These studies indicate that activation of the
complement system already commences in the donor, and that
systemic complement activation may lead to local inflammation
of the potential donor graft. As a result of inflammation, the
(donor) organs are damaged. For DBD donors it is hypothesized
that brain death initiates a sterile immune response through
the release of endogenous DAMPS. Those danger signals are
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TABLE 1 | Overview of the complement targets or therapeutics tested in the organ donor per organ, per type of donor.
Organ Species Donor type KO/treatment Study Graft injury
Kidney Rat DBD sCR1 (42) ↓
DBD C1-INH (38) ↓
Non-human primate ECD C1-INH (41) Unknown
Human DBD C1-INH NCT: 02435732 Unknown
Liver None
Intestine None
Heart Mouse DBD C3−/− (79) ↓
DBD CR2-Crry (78) ↓
Lung Mouse DBD C3aRA (100) ↓
Inclusion criteria were: (1) All animal and human models, testing (2) complement targets or therapeutics applied in the organ donor or during preservation, with (3) the donor injury
mechanism as a target of interest (e.g., DBD, DCD). Excluded are studies in which complement targets or therapeutics were tested in IRI or rejection as mechanisms of injury. ↓ The
treatment resulted in less graft injury.
released by cells under conditions of cellular stress or tissue
injury. In DBD donors, these endogenous DAMPs are either
actively secreted via stressed immune cells or passively released
from dying brain cells or damaged extracellular matrix, which
contributes to CP activation. Sterile inflammation can also cause
further tissue destruction by the release of excessive amounts
of DAMPs via necrotic cells. As a result, an extension of the
local inflammation to the systemic circulation occurs, in a similar
manner as is seen during microbial invasion. C1q and properdin
will bind to these necrotic cells, which triggers the activation
of the complement system. In addition, brain death causes an
increase in intestinal permeability, that results in the release of
pathogen-associated molecular pattern molecules (PAMPs) like
LPS. In this way, the complement system is activated via the
AP. In contrast, data referring to the pathogenic mechanisms in
DCD-induced organ injury are scarce (24, 25). Taken together,
despite the mentioned hypotheses of injury mechanisms, large
knowledge gaps exist with regards to this topic. The exact
role of complement activation and the involved complement
components have not been fully elucidated in different donor
organs and different donor types, especially in DCD donors. Of
importance, since the physiological differences between organs
and donor types might lead to various routes of immunological
activation and therefore require different therapeutic approaches.
The purpose of this review is to provide an overview of the
current knowledge on the complement system in the donor
(Table 1), the current existing knowledge gaps and future
perspectives on this topic. Furthermore, we will answer the
question if complement therapeutic should be clinically applied
in the multi-organ donor.
RENAL TRANSPLANTATION
Challenges in Renal Transplantation
The kidney was the first organ successfully transplanted, in
1954 (26). Nowadays, renal transplantation (RTx) is the optimal
treatment for patients with end-stage renal disease. Besides
experience in years, the number of performed kidney transplants
exceeds the number of all other solid organ transplants. In 2017,
4.419 renal transplants were performed in Europe, as registered
by the Eurotransplant International Foundation (Figure 2).
However, the number of patients waiting for a renal transplant is
extensive and still increasing (27). The growing shortage of donor
kidneys led to exploration of alternative strategies. First, the
number of living donations increased significantly over the years.
Living kidney donation is constantly evolving and goes nowadays
beyond relatives, like individuals who donate a kidney to an
anonymous recipient, so-called altruistic or Samaritan donation.
Besides, special programs are developed, such as the Old for
Old program or domino transplantation. In the Old for Old
program kidneys of donors over 65 years or older are donated
to recipients of the same age, without taking tissue-matching
characteristics into account (28). A domino transplant occurs
when the removed organ from first recipient is transplanted in
a second recipient (29). Furthermore, the donor pool consisting
of both DBD and DCD donors is expanded by the use of
kidneys from extended-criteria donors (ECD), which refers to
older donors and donors with comorbidities (3). Compared to
standard-criteria donor (SCD) organs, kidneys from ECD are
associated with up to a 2-fold increased risk of DGF, acute
rejection, and graft loss (30). Kidneys from older donors are
generally more immunogenic than kidneys from young donors,
which makes immunomodulatory approaches in organs from
ECDs an interesting topic for future research (30). With the
increased utility of kidneys from ECDs in the clinics, more
randomized controlled trials should be performed, with ECD
kidneys included (31). Potentially, these ECD kidneys form a
subgroup who can benefit from treatment already introduced in
the donor.
The Complement System in Renal
Transplantation
Most of the evidence for activation of the complement system
in deceased donors is known from studies which focus on the
kidney. Early studies performed by Kusaka et al. detected local
C3 deposition in kidney isografts from DBD rats 1 h post-
transplantation, while no C3 deposition was seen in living donor
controls. C3 deposition was located on the endothelial cells and
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glomeruli of DBD kidneys and could still be detected at day 5
after RTx (32). In accordance, Damman et al. showed higher
renal C3 gene expression rates in DBD rats before transplantation
than in living donors (33). No additional C3 gene expression was
found after RTx, so renal C3 is deposited as a direct result of
brain death. These results were confirmed in the human setting,
in which significantly more C3 gene expression was found in
kidney biopsies taken from DBD donors than in biopsies from
living donors. The results on transcriptional level were supported
by immunohistochemistry. C3d deposition was seen in renal
grafts from human DBD donors, but not in living donors. Again,
no additional C3d deposition was found after ischemia and
reperfusion (33). The functional importance of local C3 synthesis
is demonstrated by multiple studies. Pratt et al. showed in a
murine model that renal allografts lacking C3 production survive
more than five times as long as renal allografts that produce C3
(34). In addition, Brown et al. demonstrated that expression of C3
alleles by renal cells in the deceased human donor significantly
affect graft survival (35). However, the association between the
C3 allotypes and graft survival could not be replicated by others.
Varagunam et al. detected no significant differences between
the C3 alleles on long-term renal allograft survival in patients
(36). These results are in accordance with the study of Damman
et al. which observed that donor C3F allotypes are not associated
with renal allograft outcome after RTx. Only subgroup analysis
within the DCD group revealed a protective effect of the donor
C3F allotype for primary non-function. These divergent results
could possibly be explained by the differences in sample size and
post-transplantation follow-up data (37).
The importance of the complement system is underlined
by the in-depth analysis of the gene expression differences
between human renal allograft biopsies from living and deceased
donors. Significant renal overexpression of many complement
components were seen in deceased donor kidneys before
reperfusion (38). Primarily complement-related genes of the CP
were involved, namely C1q, C1s, C1r, C2, and C4. Factor B,
an component of the AP, was upregulated in deceased kidneys.
Similar results were seen in the whole genome microarray study
performed by Damman et al. This study shows enrichment
of both the hypoxia and complement coagulation pathways
in DBD kidneys. The same pathways were involved in the
DCD kidney, but in a later phase of transplantation, namely
during ischemia (7). Focusing on the downstream complement
components, the C5a-C5aR-axis seems to play an important role.
C5a is not only systemically upregulated in the deceased donor,
but Van Werkhoven et al. showed an increased renal tubular
expression of the C5a receptor 1 (C5aR1) (18). Altogether,
these studies suggest that the local immune activation in the
deceased renal allograft is important for the outcome after
RTx. Thus, targeted therapy interfering with (local) complement
activation before organ recovery or during organ storage is
an attractive therapeutic approach. However, assessing local
immune activation requires invasive techniques. For that reason,
using complement deposition as an indicator for organ damage
might not be preferred. A recent study by Schröppel et al.
investigated the potential for less invasive markers by evaluating
C3a andC5a levels in donor urine. They found that donor urinary
C5a levels were correlated with DGF after kidney transplantation.
However, no correlation was seen between urinary C3a and
post-transplant DGF, despite higher levels of C3a in urine from
deceased donors than in urine from healthy controls. Whether
other complement proteins measured in urine correlate with
graft function, potentially serving as biomarkers, has not yet been
elucidated (39).
Already a few complement therapeutics were tested in the
deceased kidney donor or during kidney preservation. One of the
most potent complement inhibitors is C1-esterase-inhibitor (C1-
INH). As a serine protease inhibitor, in-vitro data demonstrated
that C1 inhibitor modulates activation the classical- and lectin
pathway (40–42). Pre-clinical studies with C1-INH in the
deceased donor showed promising results. Poppelaars et al. tested
a high-dose and low-dose C1-INH in a rat model of brain death
in which C1-INH was administered 30min after confirmation
of brain death. High-dose C1-INH treatment of the DBD donor
resulted in significantly lower renal pro-inflammatory gene
expressions and decreased serum levels of IL-6. In addition, C1-
INH led to an improved renal function reflected by lower serum
creatinine levels, and less renal injury as demonstrated by lower
kidney injury molecule-1 gene expression levels (40). C1-INH is
currently tested as a treatment strategy in human DBD donors
to improve outcome after RTx (NCT02435732). At this moment,
this study is in the phase of recruiting patients. In ECD donors
C1-INH treatment might be of potential therapeutic use as well,
which is currently being investigated by Fernandez et al. in a
non-human primate model (43).
Besides C1-INH, more complement therapeutics are already
tested in the deceased donor in experimental setting. Soluble
complement receptor 1 (sCR1) was given to DBD rats and
treatment with sCR1 before and after confirmation of brain
death led in both cases to significantly improved renal allograft
function. In addition, treatment with sCR1 led to reduced renal
gene expression of IL-6, IL-1β, and TGF-β. These results provide
proof that complement inhibition in the donor is effective, even
after the confirmation of brain death (44).
Next to the use of complement therapeutics in the donor,
already a few studies tested the effect of complement therapeutics
during renal preservation. Patel et al. were the first, and evaluated
the effect of APT070, also known as Mirococept (45). Mirococept
is a membrane-localizing complement regulator, which is a
derivate from complement receptor 1. Rat donor kidneys
were perfused with Mirococept and subsequently subjected to
16 h of cold storage. After 16 h of cold storage, the kidneys
were transplanted into syngeneic recipients. APT070 perfused
renal grafts had survival rates of 64% compared to a survival
rate of 26% in control-treated renal allografts. Currently,
Mirococept is tested in a multicenter randomized controlled
trial, in which Mirococept is administered ex vivo to deceased
donor kidneys. The trial, called EMPIRIKAL, is still ongoing
and aims to evaluate the efficacy of Mirococept in reducing
the incidence of DGF in renal transplants from deceased
donors (46).
Furthermore, Lewis et al. demonstrated that pharmacological
targeting the C5aR is also of potential benefit. In this study a C5aR
antagonist named A8171−773 was used, which targets both the
C5aR1 and C5aR2 (47). Donor kidneys were flushed and stored
for 2 h with UW or UW+C5aR antagonist. Kidneys treated with
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the C5aR antagonist had significantly improved renal function
and increased graft survival compared to untreated kidneys. In
addition, the C5aR antagonist prevented renal injury, reflected
by lower gene expression levels of TNF-α and macrophage
inflammatory protein-2/CXCL2. C5 was also targeted in a recent
study, in which a monoclonal antibody against C5 was used (48).
Rat donor kidneys were cold stored for 28 h with or without anti-
C5. Treatment with anti-C5 significantly increased the survival
rate of the renal allografts from 22% to 100% after 21 days.
Another C5 complement inhibitor is the recently generated
recombinant anti-C5 antibody called Ergidina, which is coupled
to a cyclic-arginylglycylaspartic (RGD) acid-peptide. The RGD
peptide has the property to migrate to the ischemic endothelial
cell. Thus, when bound to anti-C5 it will not only be able to
migrate, but also be able to control ischemia tissue injury. In a
study of Durigutto et al. rat donor kidneys were procured and
cold stored for 24 h. Thereafter, kidneys were ex vivo infused
with Ergidina, and stored for either 15min or 30min. Results
showed that Ergidina was bound to the vascular endothelium
of the kidney and already reached a plateau after 15min. Next,
the efficacy of Ergidina was evaluated in a rat model of IRI. Rats
received Ergidina 45min before ischemia and were sacrificed at
day 1 or day 4. Ergidina preserved renal function, prevented
tissue injury at glomerular and tubular level and prevented C9
deposition in the kidneys at both day 1 and day 4 (49).
Besides anti-C5, Yu et al. also evaluated the effect of AP
inhibitor TT30. TT30 is a complement receptor 2/factor H fusion
protein. Ex vivo preservation with TT30 for 28 h significantly
improved renal function and renal graft survival compared to
control-treated kidneys. The 21-day graft survival rate was 66%
in the TT30 treated group compared to the 100% in the anti-
C5 treated group (48). These survival rates did not significantly
differ, but imply that next to the AP, activation of the CP or LP
might play an role in in ischemia-induced injury.
Based on the studies already performed, it can be hypothesized
that the renal allograft is already primed for complement
activation in the deceased donor. Therapeutics interfering
with complement activation before organ recovery would
be an attractive therapeutic approach that deserves further
investigation. Most importantly, studies using complement
therapeutics in order to prevent renal injury seem to be
most effective when the therapeutics are specifically delivered
to the site of complement activation. Therefore, with the
increased availability of new complement therapeutics, it is
crucial to unravel the role of complement system in the deceased
donor. Especially, it is essential to learn whether complement
therapeutics can be administered in the donor before organ
retrieval or if treatment after organ procurement is preferred.
LIVER TRANSPLANTATION
Challenges in Liver Transplantation
Currently, more than 1.500 liver transplantations (LiTx) are
performed in Europe per year (Figure 2). In general, LiTx is
considered for patients which suffer from acute liver failure, end-
stage liver disease and primary hepatic malignancy. However,
after a rapid growth, the annual number of LiTx has stopped
increasing over the last 10 years. An important limitation
for the stagnant number of LiTx is donor shortage (50).
Therefore, alternatives to DBD donation of liver transplants are
more frequently implemented. First, the concept of “split liver
transplantation” is used, which enables surgeons to transplant
one donor liver into two recipients. However, this technique
is only feasible with ideal livers, mostly derived from young
DBD donors. Second, there is an increase in living-related liver
transplantation. Living donation for adults is still associated
with major complications and a substantial risk for the living
donor (51). Therefore, both splitting and living LiTx have not
gainedwidespread acceptance. Finally, more extended criteria are
introduced such as advanced age, steatosis and DCD liver grafts.
Controversy exists about DCD liver transplants, since studies
that compare graft outcome from DCD donors with standard
DBD donors have been variable. Studies performed so far suggest
decreased graft survival in the first year following DCD LiTx
(52). Although ECD donation reduces the gap between supply
and demand, managing the risk for the recipient is a critical
factor in ECD donor livers. ECD livers are vulnerable to hypoxia
and tissue injury associated with DGF or graft survival. In
order to improve the quality of these suboptimal liver grafts,
several studies evaluated the effect of intervention during donor
management, such as the administration of steroids, dopamine,
and hormone replacement (10, 11, 53). Taken these data into
account, the current strategies applied in LiTx have mainly
been focusing on treatments to stabilize hemodynamic disorders
associated with deceased donation. Yet, their effects on liver
graft function and survival remain unknown. Therefore, it could
be beneficial to consider other molecular pathways involved,
including the complement system.
Complement System in Liver
Transplantation
The number of studies that investigated the role of the
complement system in deceased donation for LiTx is scarce. Of
interest, since the liver is responsible for the biosynthesis of 90%
of plasma complement components and soluble complement
regulators (54). Other type of cells including immune cells
and endothelial cells produce complement components as
well, but their contribution to plasma levels appear to be
minor compared to hepatocytes. Moreover, several complement
receptors are expressed in the liver; e.g., C5aR, CR1, CR3,
CR4, and complement receptor immunoglobulins (CRIg). These
complement receptors have multiple functions on different
cells in the liver, from inducing the acute phase response to
the clearance of C3-opsonized immune complexes. Thus, the
complement system is involved in multiple liver diseases, such
as transplant-induced injury (55).
The role of the complement system in the deceased liver is
mainly investigated in the DBD donor. Rebolledo et al. were
the first to show complement activation in DBD donor livers.
In this study, rats were subjected to brain death for a period
of 4 h. Results showed that DBD donor livers had a significant
increase in C3 mRNA levels compared to the control group.
Next, rats were pretreated with prednisolone 30min before
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induction of brain death as a proof of principle. Pretreatment
with prednisolone resulted in a reduced pro-inflammatory state,
reflected by lower mRNA levels of IL-6, IL-1β, TNF-α, and
MCP-1. In contrast, mRNA levels of C3 were upregulated in the
prednisolone treated rats (9). In an additional study, Rebolledo
et al. administered prednisolone after confirmation of brain
death to investigate treatment potential. Again, prednisolone
reduced the levels of pro-inflammatory cytokine gene expression,
but did not increase nor decrease the C3 expression compared
to untreated DBD rats. These divergent C3 expressions after
administration prednisolone are not fully understood, but could
be explained by the fact that complement is involved in liver
regeneration (11).
So far, only one study investigated the effect of complement
inhibitors on the donor liver before transplantation.
Bergamaschini et al. studied the potential of C1-inhibitor
(C1-INH) treatment during preservation. Porcine livers were
removed from donors and perfused with University ofWisconsin
(UW), with or without addition of C1-INH, and stored statically
at 4◦C for 8 h. To assess liver function, livers were subsequently
reperfused for 2 h with pig blood on an extracorporeal circuit.
Results demonstrated less complement activation, reflected by
normal levels of complement haemolytic activity and absence
of C3 activation production in both plasma and tissue at time
of reperfusion. Morphological analysis of the livers showed
significantly decreased inflammation as shown by only a
mild increase in portal and lobular inflammatory infiltration,
compared to necrotic lesions in the untreated group (56). Taken
together, C1-INH treatment during preservation seems to
protect the liver against cell injury and inflammation during the
preservation phase. Therefore, complement therapeutics in the
donor, but also the preservation phase, might be beneficial for
the liver.
Important to take into account in LiTx is the process of liver
regeneration. Liver regeneration is a process in the liver that
allows mature hepatocytes to re-enter the cell cycle, proliferate,
and eventually replace lost or damaged hepatocytes (57). Liver
regeneration is important for both donors and recipients of liver
transplants, especially in the case of a failing remnant liver after
“splitted” liver donation or transplantation of a small-for-size
liver in the recipient (58). So far, no therapy exists for these
patients, so there is a significant need for strategies that stimulate
the regenerative capacity of livers. The complement system
seems to have a key role in the liver regeneration, primarily
during the early phases, were the hepatocyte re-enters the cell
cycle and proliferates. Recently performed studies demonstrated
an important role for the complement effector proteins, C3a
and C5a (59, 60). Strey et al. subjected C3- and C5-deficient
mice to a 70% partial hepatectomy model. Deficiency of C3
or C5 led to significantly less liver regeneration, as reflected
by fatal liver failure. Reconstitution of effector molecules C3a
and C5a resulted in hepatocyte proliferation, which indicates
that C3 and C5 are key factors in regeneration of hepatocytes.
The precise role of complement in the deceased donor still
needs to be elucidated, but ischemia-reperfusion injury (IRI)
studies showed an important role for both C5a and C5b-9 in
the induction of injury (61, 62). These contradictive results
with regards to the role of complement in hepatic IRI vs. liver
regeneration emphasize the need for a fine balance between
complement activation and inhibition. Therefore, it is important
to have a good understanding of the two processes and test
potential complement inhibitors in both disease models. A
study performed by He et al. evaluated the effect of CR2-
Crry in a combined mouse model of total IRI and 70% partial
hepatectomy. CR2-Crry is a fusion protein that specifically
targets the sites of C3 activation. This study shows that CR2-
Crry is able to protect against hepatic IRI alone, however
a combination of IRI and partial hepatectomy resulted in
significant liver damage and a failure to regenerate compared
to WT mice. The failure to regenerate is probably a result of
the inability to generate sufficient levels of C3a, C5a, and C5b-9,
complement effector molecules important for liver regeneration
(63). Given these observations, CR2-CD59 might be a potential
complement therapeutic. CR2-CD59 is a fusion protein that
migrates to sites of complement activation and specifically
inhibits the MAC, without the blockage of other complement
components. CR2-CD59 was tested by Marshall et al. in the
same mouse model of total IRI and 70% partial hepatectomy as
described by He et al. The study performed by Marshall et al.
showed that livers treated with CR2-CD59 have less injury, and
more hepatic regeneration than control-treated mice. CR2-CD59
mice had a 100% 7-day survival rate, whereas in the CR2-Crry
treated group only 40% of the mice survived (64). These results
imply that in MAC-induced injury, the regenerative response
of the liver is impaired. Therefore, these studies highlight the
need for a tailor-made approach to protect the liver against
ischemia injury and enhance the regenerative capacity. Although
only a few studies are performed, they all point towards the
involvement of the complement system in the deceased donor
liver. The exact role of complement in the deceased donor
liver and its consequences on liver transplant viability and
survival remains unknown. Therefore, more studies, especially
focused on the complement-dependent balance between injury
and regeneration in the liver, need to be conducted.
INTESTINAL TRANSPLANTATION
Challenges in Intestinal Transplantation
Intestinal transplantation (ITx) is the least common form of
organ transplantation. The field of ITx is small with only
6 ITx reported in 2017 by Eurotransplant (Figure 2). ITx is
indicated for patients with intestinal failure who suffer from
life-threatening complications when using parenteral nutrition.
Despite the advances, ITx is still a challenging procedure due
to multiple factors. First, the intestine is highly immunogenic
because it consists of a large amount of lymphoid tissue,
including the patches of Peyer and the mesenteric lymph
nodes (65). Second, the intestine carries an enormous bacterial
load. These characteristics create a fine balance between the
maintenance of tolerance to healthy self-tissue and eliminating
invading pathogens.Moreover, the intestinal mucosa is extremely
vulnerable to injury, especially hypoxia injury, which is
negatively associated with graft outcome (66). As a result of
the susceptibility for hypoxia, DCD donor intestinal grafts are
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not yet accepted for ITx (67). This makes DBD donors the
sole source for intestinal grafts. Despite major achievements in
intestinal grafts retrieved from DBD donors, such as improved
immunosuppression, the physiological abnormal state in the
DBD donor still significantly compromises the viability of the
intestine. Therefore, it is concerned that ITx is underutilized
due to complex pathophysiological processes and difficulties to
identify markers for intestinal injury (68).
The Complement System in Intestinal
Transplantation
Hardly any studies are performed to unravel the
pathophysiological processes in the intestine of a deceased
donor, probably since the number of ITx performed per year
is low. However, based on the few studies there are, it is likely
that the deceased donor state causes significant alterations in
the intestine and affects intestinal barrier function. The degree
of permeability already changes in response to a low level of
pro-inflammatory cytokines, which results in the translocation of
intestinal bacteria. The intestine contains microbial LPS, which
is thought to be one of the most potent activators of the AP
of the complement system. Although studies showed that LPS
from different bacterial strains interact in qualitatively different
ways with complement, LPS from gram-negative bacteria indeed
induce consumption of complement (69). A study performed by
Koudstaal et al. confirmed the involvement of LPS in the DBD
donor by using a brain death model for rats. Rats subjected to 4 h
of brain death had higher serum levels of LPS and LPS-binding
protein (LBP), as evidence of endotoxemia. Besides, mRNA
gene expression levels of LPB were significantly higher in DBD
rats than in living controls. DBD rats had a high inflammatory
state, reflected by the strongly elevated levels of IL-6 and MCP-1
(70). The study shows enhanced intestinal permeability in
DBD rats which results in a high immunological response. The
observation that brain injury can rapidly induce significant
damages to the intestine is demonstrated by a study of Hang
et al. This study investigated the histopathological alterations of
the intestinal mucosa in rats after 3–72 h following brain injury.
The intestinal mucosa was already severely damaged after 3 h,
reflected by shedding and apoptosis of epithelial cells, mucosal
atrophy, and loss of increase in intestinal permeability. The
level of plasma endotoxin was positively related to the degree of
intestinal permeability. Compared with the control group, serum
endotoxin levels were significantly increased at 3, 12, and 24 h
with a maximal peak at 72 h. The first peak of endotoxin levels,
at 3 h, might be the result of acute gut mucosal damage due
to ischemia-induced sympathetic hyperactivation. The second
peak of serum endotoxin might be induced by mucosal damage
and increased epithelial necrosis, which occurs at 72 h (71).
Whether complement is activated in the intestine of both the
DBD and DCD donor remains to be elucidated. However, the
current findings indicate that protection of the intestine in the
multi-organ donor is necessary, since translocation of intestinal
bacteria and endotoxin lead to a systemic inflammatory
response syndrome and sepsis with subsequent multi-organ
failure (72). Further research needs to focus on the exact role
of complement activation in the deceased intestinal donor.
This could not only create a new window of opportunity for
immunosuppressive strategies, but also improve the clinical
success of ITx.
HEART TRANSPLANTATION
Challenges in Heart Transplantation
The technique for heart transplantation (HTx) was already
developed in 1967. Nevertheless, it took more than a decade
before immunosuppressive treatment strategies improved this
technique to such an extent, that HTx became the gold standard
treatment for end-stage heart diseases (73). In 2017, 548 heart
transplants were performed in Europe, as registered by the
Eurotransplant International Foundation (Figure 2). Both non-
ischemic and ischemic cardiomyopathy are the underlying
diagnoses responsible for over 80% of heart transplants (74).
The increased need for HTx over the years led to the inevitable
gap between donor demand and supply, analogous to other
donor organs. Despite the attempt to minimize this gap by the
introduction of techniques such as left ventricular assist devices
(LVAD), these therapies mainly serve as a short-term, “bridge-to-
transplant” solution.
Unfortunately, the majority of potential heart donors is
not procured and transplanted, for several reasons. First, most
countries are limited to the use of DBD hearts, and do not
utilize the DCD donor pool. Anxieties exist concerning warm
ischemic injury to the myocardium after circulatory death,
together with the inability to assess heart function. However,
new techniques are being developed to tackle these issues. In
an attempt to limit warm ischemia times, implementation of
techniques like in situ normothermic regional perfusion for
thoracic organs are explored in order to convert from a DCD
to a DBD-type procurement (75). In addition, normothermic
regional perfusion provides the opportunity to functionally assess
the donor heart. Furthermore, implementation of techniques
such as ex situ heart perfusion are being studied (76). Despite
its experimental nature it is suggested that those techniques
lead to usage of more donor hearts, with comparable outcomes
to the current gold standard of DBD HTx (77). A second
reason for low procurement rates of potential donor hearts
is the relatively strict cardiac donor selection criteria. Age <
55 years old, appropriate hemodynamics and limited inotropic
support are examples of selection criteria that impede suitability
(78). Godino et al. showed that hemodynamic dysfunction
represented the major cause for unsuitability of heart donors,
a complication that occurs frequently in DBD donors (79). In
terms of immunology, experimental transplantation models have
shown that hearts have differences in rejection patterns compared
to abdominal organs such as kidneys and livers, leading to
higher rejection rates (73). These organ-specific differences in
immunology might contribute to the differences seen in graft-
survival rates between organs in human transplantation. Of
importance, since the immunologically active state of the organ
already commences in the donor. The DBD donor has shown
to exacerbate post-transplantation cardiac IRI that reduces
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allograft survival, in which the complement system might play
a key role (80).
The Complement System in Heart
Transplantation
The role of the complement system in the deceased heart
donor has only been studied in DBD donation, which raises
questions for involvement in DCD donation. An experimental
mouse study performed by Atkinson et al. showed increased
local complement C3d deposition in the heart after brain death.
C3d deposition was primarily seen in the vascular endothelium
and surrounding myocytes, in a significantly higher amount
than in grafts from sham-operated mice. In addition, the study
demonstrated that absence of C3 reduced cardiac damage,
reflected by less endothelial swelling and lower serum levels of
cardiac troponin I. Also, significantly less leukocytes infiltrated
the heart tissue and gene expression of P-selectin, ICAM-1,
VCAM-1, TNF-α, and IL-1β were reduced upon brain death.
In order to investigate whether therapeutically targeting C3
would diminish DBD-induced cardiac damage as well, mice
were treated with CR2-Crry after receiving a living or DBD
heart. CR2-Crry is a complement inhibitor, that targets C3 split
products by binding local C3b deposits. Upon treatment with
CR2-Crry, recipients who received DBD donor hearts showed
reduced cardiac troponin I levels and histological injury scores,
similar to levels of living transplanted hearts. Thereby, CR2-Crry
treatment diminished neutrophil and macrophage infiltration
and prolonged allograft survival of treated DBD donor hearts
compared to untreated controls (81).
Based on these studies, it is suggested that complement
inhibitory strategies applied to the deceased donor may provide
protection of the heart graft. To see whether the results seen in
rodent models are clinically relevant, Atkinson et al. analyzed
complement deposition in human DBD heart biopsies and
living donors. The human biopsies taken from DBD donors
before implantation showed C3d complement deposition and
inflammation in all grafts, compared to minimal C3d deposition
in biopsies from living donor hearts. The complement staining
patterns in human DBD hearts demonstrate that complement
activation already occurs in the DBD heart, independently from
the ischemia-reperfusion phase (80). However, the contribution
of each activation pathway of the complement system in DBD
heart injury is not fully known. The CP might be involved,
since IgM complexes show similar distribution patterns as seen
for C3d staining in murine DBD hearts (81). In human heart
biopsies from both DBD and living donors stained for C4d,
50% of the cases showed C4d deposition in DBD biopsies before
implantation into the recipient. In contrast, living donor hearts
showed no C4d deposition at all, which suggests a potential role
for the CP in DBD-induced heart injury (80). Whether the other
complement activation pathways are involved as well-needs to
be further elucidated. Furthermore, the role of the complement
system in DCD heart donation requires additional attention.
Zhang et al. investigated the role of natural immunoglobulins in
a model for myocardial warm IRI and revealed that pre-existing
IgM’s, which recognize “ischemic antigens,” are the main initiator
of pathology through activation of the complement system (82).
Regarding variable warm-ischemia times in DCD donors, this
might be an interesting field of future research.
LUNG TRANSPLANTATION
Challenges in Lung Transplantation
In 2017, 1.233 lung transplants have been performed in Europe,
as registered by the Eurotransplant International Foundation
(Figure 2). The most important indications for bilateral lung
transplantation (LuTx) are Chronic Obstructive Pulmonary
Disease (COPD), Cystic Fibrosis (CF), Interstitial Pulmonary
Fibrosis (IPF), and Primary Pulmonary Arterial Hypertension
(PPAH) (83). Although the number of LuTx is much lower than
the numbers of abdominal organs transplanted, donor shortage
is an important issue in LuTx as well. This observation is mainly
the result of a lower utilization rate of lungs than of abdominal
organs. More than 70% of the donor livers and kidneys are
procured and used for transplantation, while lungs are only
suitable for transplantation in around 20% of the cases (84).
Lung injury is an important reason for excluding donor lungs for
transplantation and is caused by the process of donor death and
complications at the intensive-care unit (85).
Most donor lungs are procured from DBD donors, in
which the process of brain death leads to inflammation and
pericapillary leakage, resulting in pulmonary edema (86). Those
mechanisms of injury make the lung more susceptible to IRI
and lead to poor graft survival rates of only 54% after 5 years
(87). The last years attempts have been made to enlarge the
donor pool. Examples are transplantation of lungs from DCD
3 donors (88), usage of ECD (89), living-donor lobar lung
transplantation (90), and application of the technique of ex
vivo lung perfusion (EVLP) in an attempt to test and repair
discarded donor lungs (91, 92). So far, those attempts have
demonstrated similar outcomes on graft survival compared to
standard DBD lungs (93, 94). However, those efforts have not
yet closed the gap between supply and demand in LuTx and
did not lead to improved graft survival. In an immunological
point of view the lung is an interesting organ, because of
continuous exposition to the outside environment, serving as a
first line barrier to infection. As a result, the immunomodulation
regimen in lung transplant recipients makes those patients
more prone to fungal infections (95). This issue emphasizes the
challenge to create a balance between infection and rejection.
In order to do so, the exact immunological pathways involved
in donor lung injury need to be further elucidated before
development of novel immunosuppressive strategies, which
tackle the issues of donor shortage and graft survival in the field
of LuTx.
The Complement System in Lung
Transplantation
Complement in LuTx has mostly been studied in recipients,
focused on the role of the complement system on lung IRI
and rejection. However, Budding et al. demonstrated that
the complement system is already involved from the first
step of the lung transplantation process. The study showed
Frontiers in Immunology | www.frontiersin.org 9 February 2019 | Volume 10 | Article 329
van Zanden et al. Complement Therapeutics in Multi-Organ Donors
that recipients who received a donor lung with a CD59
protein single nucleotide polymorphism (SNP) configuration,
had a higher risk for chronic rejection after LuTx. Under
normal circumstances CD59 acts as a regulatory protein, which
suppresses MAC formation by binding C9 to C5b-C8 complexes,
which results into inhibited cell lysis. The presence of a CD59
SNP configuration affects CD59 expression and sensitivity to
complement-mediated cell lysis, which increases the risk for
rejection in recipients who receive a CD59 SNP donor lung
(96). These results suggest that C5b-9 is involved in donor-
related lung injury. However, considering the direct effects of
complement split-products like C3a and C5a produced in the
earlier steps of the complement system, the question is raised
whether regulatory proteins of the terminal pathway should be
the target of interest. In lungs, C5a, but also C3a, have shown
to induce acute pulmonary injury by constriction of smooth
muscle walls in bronchioles and pulmonary arteries, and cause
focal atelectasis (97). C3a levels in plasma have additionally
been described to be associated with later development of
acute respiratory distress syndrome (ARDS) in polytrauma
patients (98). Furthermore, C3a and C5a are described to attract
and activate neutrophils (99, 100). Of importance, since the
amount of recruited and infiltrated neutrophils are associated
with graft survival after LuTx (101). The beneficial effect
of targeting the donor lung on the level of C3a has been
demonstrated by Cheng et al. in a mouse model for LuTx. First,
the study confirmed that the process of brain death induces
donor lung injury. Pathology lung injury scores examining
congestion, hemorrhage and inflammation, were significantly
increased. Secondly, the amount of infiltrated neutrophils and
macrophages were elevated in DBD mice compared to both
sham-operated mice and living donor mice. Furthermore, a
significantly elevated expression of complement receptor C3a
(C3aR) in DBD donor lungs was found. The C3aR was
mainly expressed on bronchial and epithelial cells and lung
endothelium. Thereafter, targeting the C3aR with a nebulized
complement C3a receptor antagonist was tested in a mouse
model of LuTx. Recipients of untreatedDBDdonor lungs showed
aggravated IRI and acute rejection (AR) grades, which was
ameliorated after treatment with the C3aR antagonist. IRI and
AR grades were even returned to levels as seen after living-donor
LuTx (102).
Despite the limited amount of research performed on the
topic of DBD-related lung injury, it is suggested that the
complement system is already involved from the first step
of the process, namely the donor. Of particular interest,
given the observation that lungs locally produce complement
proteins. Pulmonary alveolar type II epithelial cells generate
proteins of the CP and AP, in particular C2, C3, C4, C5,
and factor B (103). Besides that, human bronchiolar epithelial
cells are able to synthesize C3 (104). However, literature
on the mechanisms of the complement system in the lung
donor and the contribution of local complement production
in this pathophysiology is scarce. Which specific pathway
should be the target of interest, and if treatment focused on
those components will lead to improved graft survival without
compromised defense mechanisms against pathogens, needs to
be further investigated.
FUTURE PERSPECTIVES
The complement system regained new interest in the field
of transplantation and the amount of acquired knowledge is
increasing. The complement system was first studied in RTx,
revealing its potential role in reperfusion injury and survival.
However, new studies elucidated that the complement system
already plays a role from the first step of the transplantation
process, in the donor (33). Other studies showed that this damage
accumulates throughout the rest of the transplantation process
(81). Striving to restore an immunologically active organ before
implementation in the recipient may have advantages, in favor
of transplantation outcomes in patients. The complement system
might be a potential therapeutic target for this purpose, and
not only in the field of RTx. However, multiple knowledge
gaps exist with regards to the role of the complement system
throughout the transplantation process. Those need to be
elucidated before therapeutics can be implemented in the clinical
setting. For some organs, the pace of research developments can
be complicated by the small number of transplants performed.
The intestines, for example, has only been transplanted 6
times in 2017, as registered by the Eurotransplant International
Foundation (Figure 2).
One of the questions that remains unanswered regarding
complement-targeted interventions is the optimal timing of
drug delivery to the donor graft. Different timing possibilities
are (1) treatment in the organ donor, (2) during preservation,
or (3) after implementation in the recipient. The main
benefit of treating the organ donor is the opportunity to
target the immunologically active state of the organs, nearly
directly after the damage has occurred. However, it should
be considered that all organs will be subjected to the same
type and dose of treatment. An important disadvantage of
this strategy is the risk that not all donor organs benefit
from the same treatment. One organ might benefit from
certain therapy, while the other organ might be even negatively
affected. This is of particular importance for the liver, given
the fine balance between injury and regeneration in this
organ (63, 64).
The preservation state, however, provides a window of
opportunity to treat the organ in an isolated manner. Various
approaches are herein possible, which depends on the method of
preservation. Cold static storage is the preservation technique
with the longest history and is mostly used (1). Therapeutics can
be added to the storage solution or organs can be infused just
before cold static storage. The latter approach was demonstrated
by Durigutto et al. who infused renal allografts with a targeted
complement inhibitor, with beneficial results after reperfusion
(49). However, the technique of cold storage is increasingly
taken over by ex vivo perfusion systems. Various strategies in
ex vivo perfusion are being practiced such as different perfusion
solutions and perfusion temperatures (1). Nevertheless, in all
ex vivo perfusion strategies blood flow through the organ is
mimicked, thereby reducing ischemia times. Besides, oxygen and
other additives can be supplemented to the perfusate solution
in order to preserve or improve the quality of the organ, which
provides opportunities for complement therapeutics as well.
In the lungs, even ex vivo inhalation of therapeutics can be
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considered as route of administration. An important benefit
of treating the organ in an isolated manner is that a lower
treatment dose might be required, especially in in organs with
little metabolic activity. This might lower costs of complement-
targeted therapies. However, little is known about the approach
of treatment during preservation, especially with regards to the
effect of treatment on donor-related injury. The few experimental
studies that have been performed have mainly focused on
preventing or diminishing IRI, by treating unharmed, “healthy”
organs with complement inhibitors during the preservation
phase (48, 56, 105). Therefore, the question whether inhibiting
complement during the preservation phase has an effect on
deceased donor-related injury as well, should still be investigated.
Furthermore, it should be considered that the complement
system might be activated by interaction with foreign
materials (106).
Finally, treatment of the organ after implementation in
the recipient should be considered as a possible timing of
drug delivery. It should be emphasized that donor-related
graft injury is amplified by the inevitable event of IRI (81).
Beneficial effects of treatment applied in the organ donor or
the isolated graft might not cover this second-hit of injury,
occurring in the latter phase of the transplantation process.
Application of complement-therapeutics in the recipient might
tackle this issue, as demonstrated by Ferraresso et al. in
a rat model for HTx. They showed that treatment of the
recipient with anti-C5 therapy prior to reperfusion, prevented
IRI-induced graft injury (107). Nevertheless, possible adverse
side effects of complement therapeutics in the recipient
need to be elucidated before implementation in the clinics.
Finally, it can be considered to combine multiple time
points of drug delivery, of which the net effects need to be
further studied.
Another unanswered question is the translatability of results
from one organ, to other organ systems. Especially since most
knowledge on the involvement of complement is gained from
research in deceased donor kidneys, it is questioned whether
those findings apply to other organs as well. In order to
answer this, more studies are needed that focus on unraveling
the mechanisms of complement activation, specifically per
organ and donor type. Especially, given the physiological
dissimilarities between organs and the differences in mechanisms
of pathophysiology between DBD and DCD donors. The role of
the complement system has been underexposed mostly in DCD
donation. Yet this will be of growing importance, since DCD
donors are increasingly deployed in an attempt to expand the
donor pool.
CONCLUSION
In conclusion, it has become evident that the complement system
plays an important role in the donor, affecting all potential
donor organs. To answer the question whether complement
therapeutics should be clinically applied in the multi-organ
donor, several uncertainties need to be elucidated first. These
uncertainties include the timing, route of drug delivery and
optimal target of complement therapeutics, complicated by
dissimilarities in the pathophysiology of organs and differences
between donor types. A tailor-made approach for each donor
organ is pursued, aiming to improve the quality of donor grafts
that possibly leads to an enlargement of the donor pool and
improved outcomes after transplantation.
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